Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist - Wikidata - wikimedia - TriplyDB

Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist

Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist

http://www.wikidata.org/entity/Q35045639

about

sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats.Intestinal lipid alterations occur prior to antibody-induced prostaglandin E2 production in a mouse model of ischemia/reperfusion Effects of intestinal mucosal blood flow and motility on intestinal mucosa.Polyunsaturated fatty acid metabolism signature in ischemia differs from reperfusion in mouse intestine.Inhibition of sPLA₂-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA₂α pathway in mice cerebral cortex.Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats.An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats miR-203 regulates nociceptive sensitization after incision by controlling phospholipase A2 activating protein expression.Arginyl-glutamine dipeptide or docosahexaenoic acid attenuates hyperoxia-induced small intestinal injury in neonatal mice TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion-induced damage.Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes Ketamine anesthesia reduces intestinal ischemia/reperfusion injury in rats.Cysteinyl-leukotriene receptor antagonism blunts the acute hypotensive response to endotoxin in cats.Comparative effects of triflusal, S-adenosylmethionine, and dextromethorphan over intestinal ischemia/reperfusion injury

P2860

Q24635932-7AE53F8A-96F4-427F-999C-2B88F6FF251C Q26997377-A0519FEB-B6BF-46D5-8E58-642D9A018189 Q28581568-FDE5982A-AB0F-476A-B58F-A878C847CDE1 Q33576806-439966AB-CC77-466E-B6ED-9CDAEE27911F Q33678586-D2652130-C4AF-48EE-8943-B18413061C9B Q33829672-18E08686-7D22-481F-9BBC-0068250B48DC Q35000900-A4DFFF45-E8D6-49A9-BDC0-3A79E4425DCE Q35018919-DA49E735-03DA-41C2-B0F8-F8DF098AE0B9 Q35092909-D378EE9B-4704-4C6D-A88C-2E2FEA1F3552 Q35202866-827E7976-A082-4E61-ACF0-23693CE445F7 Q36135119-AD023A96-4427-4A04-9389-A65339D27EE4 Q36182494-A0D21C71-2CD0-473D-8088-A00EE5F51A97 Q36197696-84C5C4E4-BD54-41B3-81D9-6932C902BE02 Q37111037-1EE9D315-E77D-4F70-BE5A-EFE95A546B86 Q37362932-040B414A-FC37-4A73-8C4A-B0BF641D8779 Q37485758-7D4EB64A-49FD-4C05-915D-C3018B51DEC3 Q42555443-E2B92585-84CC-4758-B645-643A4A5900ED Q42933777-DB4FCE8E-EEC7-4FB7-89EE-CAD30A7A6BE1 Q58694385-DD23F6EE-74E4-4F3F-9C75-B8D613D9FA71

P2860

Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist

http://www.wikidata.org/entity/Q35045639

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Comparative protection against ...... nd an LTC4 receptor antagonist

@en

type

label

Comparative protection against ...... nd an LTC4 receptor antagonist

@en

prefLabel

Comparative protection against ...... nd an LTC4 receptor antagonist

@en

P1433

Q35045639-1F32BE74-99CA-4002-AF28-151A27E114D1

P1476

Q35045639-7A5047C1-A9E8-4B55-ACE1-A411DD125B67

P2093

Q35045639-1DEC1171-2F5A-4501-B95F-199B5788A620

Q35045639-37E07CFD-EA27-4639-ACE6-C683B18CE964

Q35045639-45EBF6AF-21EB-404A-BBDD-3F3E9158D506

Q35045639-5A3AEE01-FC5C-455C-A8CA-26CEB880BCC0

Q35045639-D15F04EC-C72B-49D0-BA5C-5B66A052ABC1

Q35045639-FC1F76D7-488B-423E-94F7-F17FE2ABDB5A

P2860

Q35045639-118A607C-8736-471C-A7F3-D4B723FDC7B7

Q35045639-163D600F-E74B-4659-A989-4A2BC7FC9873

Q35045639-1D6D654A-A6A8-452E-B17A-AD27B29C8739

Q35045639-1EDAB398-3054-4C78-BB3E-90BD4DBFAE70

Q35045639-2364D4D3-C3D6-492C-9EDF-125523D05EEB

Q35045639-271B814A-9D47-4AD9-B20D-C72E1C1E24F7

Q35045639-295B20D5-9C11-4E2B-899E-913D712026BF

Q35045639-2B8700AF-BB1A-4029-9CA9-D5AB480F4812

Q35045639-2C429A92-6A64-4361-A3AB-4FCE0166EAD3

Q35045639-306035B2-B98C-4D77-AA98-A2F72AA10441

P304

Q35045639-649F2465-8857-4CF1-88C2-427678946AF9

P31

Q35045639-658BDF53-3E47-4377-9323-F1AAFCC41521

P356

Q35045639-67C886E8-240F-4E98-B88A-47BA75572B94

P407

Q35045639-F804572F-82F4-4DB2-8EED-97E70D9A6052

P433

Q35045639-77096B67-C438-4058-BC5B-330D276B7AEB

P478

Q35045639-6F3851FE-D362-4048-8D4F-5CC6EA22A846

P50

Q35045639-C395AD11-269F-4CCA-9C7B-61F3BD4F30E8

Q35045639-CC9FA1BF-295C-43E1-BF68-09A5B7E00872

Q35045639-E0022781-287F-43E0-AD9B-31102C37EC90

P577

Q35045639-EB97AD6A-C9C1-4965-8CA9-96063F4BAA51

P5875

Q35045639-3016AF6B-8FA1-4F12-9802-C8AA2E58A15B

P698

Q35045639-EB4E53BD-F9E0-4677-867F-1609E1A37C7D

P921

Q35045639-036941B3-B925-4A2B-9F39-EDA4A6447E4C

P932

Q35045639-E88DE8F9-5B75-4421-B3B5-AE425B90E3EB

P356

P1433

British Journal of Pharmacology

P1476

Comparative protection against ...... nd an LTC4 receptor antagonist

@en

P2093

Ian A Shiels

http://www.w3.org/2001/XMLSchema#string

Lavinia M Proctor

http://www.w3.org/2001/XMLSchema#string

Michelle Newman

http://www.w3.org/2001/XMLSchema#string

Naomi Arnold

http://www.w3.org/2001/XMLSchema#string

Stephen M Taylor

http://www.w3.org/2001/XMLSchema#string

Thiruma V Arumugam

http://www.w3.org/2001/XMLSchema#string

P2860

D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity

Superoxide radicals in feline intestinal ischemia

Expression and characterization of human group V phospholipase A2

Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions

The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2

Phospholipase A2: function and pharmacological regulation

Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats.

Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat.

Regulation and inhibition of phospholipase A2.

Phospholipase A2 enzymes in eicosanoid generation.

P304

71-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0705402

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

David P. Fairlie

Karl A. Hansford

P577

2003-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10572931

http://www.w3.org/2001/XMLSchema#string

P698

12967936

http://www.w3.org/2001/XMLSchema#string

P921

reperfusion injury

P932

1574000

http://www.w3.org/2001/XMLSchema#string